VEGFA and pancreatic ductal adenocarcinoma: More interestingly, recent study suggested the treatment of an anti-VEGFA monoclonal antibody in pancreatic ductal adenocarcinoma lead to SRC kinase-induced phosphorylation of PEAK1 in a collagen-dependent manner41.